Latest Developments in Global Genital Warts Market

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Latest Developments in Global Genital Warts Market

  • Pharmaceutical
  • Published Report
  • Jan 2025
  • Global
  • 350 Pages
  • No of Tables: 622
  • No of Figures: 83

  • In March 2024, Merck announced plans to develop an innovative investigational multivalent HPV vaccine aimed at expanding protection across various HPV strains. Clinical trials will be conducted in both males and females to assess the safety and efficacy of a single-dose regimen of GARDASIL 9 compared to the existing three-dose regimen, promising broader protection
  • In March 2024, Verrica Pharmaceuticals Inc. revealed that its lead medication, YCANTH, has earned New Chemical Entity (NCE) status from the U.S. FDA. This designation, along with its listing in the FDA's Orange Book, ensures at least five years of regulatory exclusivity, significantly enhancing the company's market position and competitive edge
  • In January 2024, Verrica Pharmaceuticals Inc. disclosed receiving the minutes from their Type C meeting with the U.S. FDA, held on November 6, 2023. The meeting aimed to review the Phase 3 clinical development strategy for YCANTH, a treatment for warts, marking a critical milestone in advancing the treatment’s regulatory and clinical progression
  • In June 2023, The Joint Committee on Vaccination and Immunisation (JCVI) recommended a shift in the HPV vaccination approach. Starting September 2023, teenagers and eligible gay, bisexual, and men who have sex with men (GBMSM) under 25 years will only receive a single HPV vaccine dose, reducing the previous multi-dose requirement
  • In June 2020, Merck Sharp & Dohme Corp., a Merck & Co., Inc. subsidiary, announced FDA approval for GARDASIL 9, a 9-valent HPV vaccine, for the prevention of various HPV-related cancers, including cervical, anal, and oropharyngeal cancers. The approval addressed unmet clinical needs, expanded vaccine distribution to hospitals and research institutes, and drove product sales growth

Frequently Asked Questions

The market is segmented based on Segmentation, By Morphology (Cauliflower-Like, Smooth Papular, Keratotic, and Flat Warts), Type (Prevention, Diagnostics, and Treatment), Cause (HPV 6, HPV 11, andOthers), Location (Vulva, Cervix Uteri, Urethra, Anus, and Scrotum), Gender (Male and Female), Dosage (Cream, Gel, Ointment, Intramuscularly and Others), End-User (Hospitals, Diagnostic Centers, Surgical Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Pharmacy Stores and Others) – Industry Trends and Forecast to 2032 .
The Global Genital Warts Market size was valued at USD 8.39 USD Billion in 2024.
The Global Genital Warts Market is projected to grow at a CAGR of 6.8% during the forecast period of 2025 to 2032.
The major players operating in the market include Bausch Health Companies , CryoSurgery , Merck Sharpe & Dohme Corp, Taro Pharmaceutical Industries Ltd, Glenmark Pharmaceutical , USA, Edge Pharma, CryoConcepts LP, CryoIQ, GlaxoSmithKline plc, ANI Pharmaceuticals , Cassiopea , Verrica Pharmaceuticals, Novan , BioNTech S.E, Serum Institute of India Pvt Ltd, Fotona, Orgenesis , Perrigo Company plc.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.